{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% Confidence Interval unavailable due to high censoring.","groupId":"OG000","lowerLimit":"33.05","upperLimit":"NA","value":"33.05"},{"comment":"Data not available due to high censoring.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"description":"Overall survival was defined as the time from randomization until death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data will be censored on the last date the participant is known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"160 mg Selpercatinib administered orally BID continuously in 21-day cycles.","id":"OG000","title":"Selpercatinib"},{"description":"Pemetrexed 500 mg/m2, IV on Day 1 Q3W plus investigator's choice of carboplatin (AUC 5 \\[maximum dose 750 mg\\] IV) or cisplatin 75mg/m2, IV on Day 1 Q3W for 4 cycles, plus investigator's choice with or without 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.","id":"OG001","title":"Pemetrexed and Platinum With or Without Pembrolizumab"}],"paramType":"MEDIAN","populationDescription":"ITT Population: All randomized participants, even if a participant did not take the assigned treatment, did not receive the correct treatment, or otherwise did not follow the protocol. Participants were analyzed according to the treatment arm they were assigned to regardless of what actual treatment they received. Participants censored: TRT A: 127; TRT B: 84.","reportingStatus":"POSTED","timeFrame":"Baseline to Date of Death from Any Cause Up to 38 Months","title":"OS (With or Without Pembrolizumab)","type":"SECONDARY","unitOfMeasure":"Months"}